Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 155

1.

Non-small cell lung cancer in the very young: Higher EGFR/ALK mutation proportion than the elder.

He CH, Shih JF, Lai SL, Chen YM.

J Chin Med Assoc. 2020 Mar 26. doi: 10.1097/JCMA.0000000000000311. [Epub ahead of print]

PMID:
32221155
2.

First Line Combination Immunotherapy for Metastatic Non-Small-Cell Lung Cancer.

Chen YM.

J Chin Med Assoc. 2020 Mar 2. doi: 10.1097/JCMA.0000000000000287. [Epub ahead of print]

PMID:
32132380
3.

Nivolumab safety and efficacy in advanced, platinum-resistant, non-small cell lung cancer, radical radiotherapy-ineligible patients: A phase II study in Taiwan.

Chen YM, Chih-Hsin Yang J, Su WC, Chong IW, Hsia TC, Lin MC, Chang GC, Chiu CH, Ho CC, Wu SY, Hung JY, Wang CC, Yang TY, Yu CJ.

J Formos Med Assoc. 2020 Feb 21. pii: S0929-6646(20)30008-5. doi: 10.1016/j.jfma.2020.01.004. [Epub ahead of print]

4.

Predicting Lung Cancer Occurrence in Never-Smoking Females in Asia: TNSF-SQ, a Prediction Model.

Chien LH, Chen CH, Chen TY, Chang GC, Tsai YH, Hsiao CF, Chen KY, Su WC, Wang WC, Huang MS, Chen YM, Chen CY, Liang SK, Chen CY, Wang CL, Lee MH, Chung RH, Tsai FY, Hu JW, Katki HA, Chatterjee N, Chanock SJ, Rothman N, Lan Q, Yang PC, Chen CJ, Chang IS, Hsiung CA.

Cancer Epidemiol Biomarkers Prev. 2020 Feb;29(2):452-459. doi: 10.1158/1055-9965.EPI-19-1221. Epub 2019 Dec 17.

5.

S-1 plus cisplatin as first-line treatment of patients with advanced non-small cell lung cancer in Taiwan.

Lai CL, Wei YF, Hsia TC, Chang GC, Wu JT, Chen JY, Chen YM.

Asia Pac J Clin Oncol. 2020 Apr;16(2):e68-e73. doi: 10.1111/ajco.13294. Epub 2019 Nov 26.

PMID:
31773897
6.

Efficacy of Paclitaxel plus TS1 against previously treated EGFR mutated non-small cell lung cancer.

Tseng YH, Shih JF, Chao HS, Chen YM.

PeerJ. 2019 Sep 24;7:e7767. doi: 10.7717/peerj.7767. eCollection 2019.

7.

Impact of Intermittent Hypoxia on Sepsis Outcomes in a Murine Model.

Chou KT, Cheng SC, Huang SF, Perng DW, Chang SC, Chen YM, Hsu HS, Hung SC.

Sci Rep. 2019 Sep 9;9(1):12900. doi: 10.1038/s41598-019-49381-w.

8.

ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer.

Marinis F, Wu YL, de Castro G Jr, Chang GC, Chen YM, Cho BC, Freitas HC, Jiang L, Kim SW, Martin C, Metro G, Provencio M, Vansteenkiste J, Vicente D, Zhou Q, Miranda MF, Bakker NA, Rigas JR, Cheema PK.

Future Oncol. 2019 Sep;15(26):3003-3014. doi: 10.2217/fon-2019-0324. Epub 2019 Jul 24.

PMID:
31339357
9.

5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study.

Luo YH, Luo L, Wampfler JA, Wang Y, Liu D, Chen YM, Adjei AA, Midthun DE, Yang P.

Lancet Oncol. 2019 Aug;20(8):1098-1108. doi: 10.1016/S1470-2045(19)30329-8. Epub 2019 Jun 26.

10.

A phase 0 study of the pharmacokinetics, biodistribution, and dosimetry of 188Re-liposome in patients with metastatic tumors.

Wang SJ, Huang WS, Chuang CM, Chang CH, Lee TW, Ting G, Chen MH, Chang PM, Chao TC, Teng HW, Chao Y, Chen YM, Lin TP, Chang YJ, Chen SJ, Huang YR, Lan KL.

EJNMMI Res. 2019 May 22;9(1):46. doi: 10.1186/s13550-019-0509-6.

11.

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Kurata T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Faivre-Finn C, Reck M, Vansteenkiste J, Spigel DR, Wadsworth C, Melillo G, Taboada M, Dennis PA, Özgüroğlu M; PACIFIC Investigators.

N Engl J Med. 2018 Dec 13;379(24):2342-2350. doi: 10.1056/NEJMoa1809697. Epub 2018 Sep 25.

PMID:
30280658
12.

Prognostic factors and first-line treatment modalities in nonagenarian patients with lung cancer.

Hsu CC, Huang YT, Tseng YH, Luo YH, Chen YM.

J Geriatr Oncol. 2019 May;10(3):439-441. doi: 10.1016/j.jgo.2018.07.013. Epub 2018 Aug 11. No abstract available.

PMID:
30104158
13.

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study.

Garassino MC, Cho BC, Kim JH, Mazières J, Vansteenkiste J, Lena H, Corral Jaime J, Gray JE, Powderly J, Chouaid C, Bidoli P, Wheatley-Price P, Park K, Soo RA, Huang Y, Wadsworth C, Dennis PA, Rizvi NA; ATLANTIC Investigators.

Lancet Oncol. 2018 Apr;19(4):521-536. doi: 10.1016/S1470-2045(18)30144-X. Epub 2018 Mar 12.

PMID:
29545095
14.

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib.

Vishwanathan K, Dickinson PA, So K, Thomas K, Chen YM, De Castro Carpeño J, Dingemans AC, Kim HR, Kim JH, Krebs MG, Chih-Hsin Yang J, Bui K, Weilert D, Harvey RD.

Br J Clin Pharmacol. 2018 Jun;84(6):1156-1169. doi: 10.1111/bcp.13534. Epub 2018 Mar 23.

15.

PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion.

Tseng YH, Ho HL, Lai CR, Luo YH, Tseng YC, Whang-Peng J, Lin YH, Chou TY, Chen YM.

J Thorac Oncol. 2018 Mar;13(3):447-453. doi: 10.1016/j.jtho.2017.10.034. Epub 2017 Dec 12.

16.

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpeño J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, Özgüroğlu M; PACIFIC Investigators.

N Engl J Med. 2017 Nov 16;377(20):1919-1929. doi: 10.1056/NEJMoa1709937. Epub 2017 Sep 8.

17.

First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer.

Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, Felip E, van den Heuvel MM, Ciuleanu TE, Badin F, Ready N, Hiltermann TJN, Nair S, Juergens R, Peters S, Minenza E, Wrangle JM, Rodriguez-Abreu D, Borghaei H, Blumenschein GR Jr, Villaruz LC, Havel L, Krejci J, Corral Jaime J, Chang H, Geese WJ, Bhagavatheeswaran P, Chen AC, Socinski MA; CheckMate 026 Investigators.

N Engl J Med. 2017 Jun 22;376(25):2415-2426. doi: 10.1056/NEJMoa1613493.

18.

Sleep disorders and an increased risk of Parkinson's disease in individuals with non-apnea sleep disorders: a population-based cohort study.

Hsiao YH, Chen YT, Tseng CM, Wu LA, Perng DW, Chen YM, Chen TJ, Chang SC, Chou KT.

J Sleep Res. 2017 Oct;26(5):623-628. doi: 10.1111/jsr.12545. Epub 2017 May 4.

19.

Comorbidities and risk of mortality in patients with sleep apnea.

Chiang CL, Chen YT, Wang KL, Su VY, Wu LA, Perng DW, Chang SC, Chen YM, Chen TJ, Chou KT.

Ann Med. 2017 Aug;49(5):377-383. doi: 10.1080/07853890.2017.1282167. Epub 2017 Feb 10.

PMID:
28276869
20.

Predictive factors for EGFR-tyrosine kinase inhibitor retreatment in patients with EGFR-mutated non-small-cell lung cancer - A multicenter retrospective SEQUENCE study.

Chang GC, Tseng CH, Hsu KH, Yu CJ, Yang CT, Chen KC, Yang TY, Tseng JS, Liu CY, Liao WY, Hsia TC, Tu CY, Lin MC, Tsai YH, Hsieh MJ, Wu WS, Chen YM.

Lung Cancer. 2017 Feb;104:58-64. doi: 10.1016/j.lungcan.2016.12.002. Epub 2016 Dec 14.

PMID:
28213001

Supplemental Content

Loading ...
Support Center